Loading stock data…
DTIL
$7.28+0.13 (+1.82%)
Market ClosedLast close May 1
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Precision BioSciences, Inc. in the Healthcare sector is trading at $7.28. The stock is currently 17% below its 52-week high of $8.82, remaining 37.9% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why DTIL maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.28
Potential Upside
5%
Whystock Fair Value$7.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$32.00+339.6%
Range$19.00 – $60.00
Fundamentals
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$204.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-84.83%
Volume
Today's trading volume
237,315
Recent News
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of +271.43% and +178.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences: Q4 Earnings Snapshot
The Durham, North Carolina-based company said it had profit of $1.05 per share. Earnings, adjusted for one-time gains and costs, were 36 cents per share. The genome editing company posted revenue of $34.2 million in the period.